Phase 1/2 study of weekly paclitaxel with or without alisertib, an investigational aurora a kinase inhibitor: Phase 1 results in patients with recurrent epithelial ovarian, fallopian tube, primary peritoneal, or breast cancer

Objective: Aurora A kinase (AAK) is a key mitotic regulator associated with microtubule organization and mitotic entry and is a negative prognostic marker in breast and ovarian, fallopian tube, or primary peritoneal cancers (OC). Preclinical data indicate that blockade of AAK signaling in OC can enhance the activity of taxane-based chemotherapy. Preliminary phase 1 results from the ongoing phase 1/2 trial (NCT01091428) are reported.